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Background
Most published histopathology studies (describing histologi-
cal characteristics of existing or new entities, existing or new
markers detected by immunohistochemistry, in situ hybridiza-
tion or molecular methods in tumor material often in relation
to patient outcome) are retrospective and use tissue samples
from a single center only. This limits the quality of the evi-
dence provided in such a paper. A higher level of evidence,
such as would be required to justify implementation in daily
clinical practice, can be reached for tissue-based biomarkers
by systematic review of published studies and meta-analysis
of the provided data.
In such meta-analyses, only research data of sufficient
quality should be used. Universally accepted criteria for the
assessment of data quality do not exist. However, an essential
element would be reporting at a sufficient level of detail of the
key components that make up the body of evidence presented
in any particular paper. This would also facilitate repetition of
the experiments performed and of the relevant observations,
an essential step as reproducibility is an absolute prerequisite
for validation of tissue biomarkers prior to their implementa-
tion in clinical practice.
For in situ hybridization and immunohistochemistry bio-
markers, the minimum information specification for in situ
hybridization and immunohistochemistry experiments
(MISFISHIE) guidelines have been developed to ensure that
a report contains sufficient detail of the assay used [1].
MISFISHIE guidelines identify six types of information to
be provided for each experiment: experimental design, bioma-
terials (biospecimens used) and treatments (preanalytical con-
ditions such as fixation and embedding), reporters (antibodies
and probes), staining (fluorescence or chromogenic), imaging
data (how images were obtained), and image characterization
(how information was extracted from the images, including
quantification of relevant image elements). However, they do
not focus on statistics (correlation of image-derived informa-
tion with clinical data) or interpretation of the results, which
are essential elements of a scientific paper.
To improve possibilities to compare results across studies
involving molecular prognostic biomarkers, the Reporting
Recommendations for Tumor Marker Prognostic Studies
(REMARK) guidelines have been developed. These are
intended to facilitate evaluation of the appropriateness and
quality of study design, used methods, approaches applied to
data analysis, and presentation of the results [2]. The
REMARK guidelines can also be used for the reporting of
biomarker studies that are not strictly molecular, such as those
reporting retrospective histopathological observations, al-
though some items on the checklist will then be less applica-
ble. Notably, the building of prognostic models, checking
model assumptions, model validation, and internal validation
might not be feasible.
In view of a perceived need for better standardization of
retrospective histopathology studies, we have used the
REMARK guidelines as a blueprint for the development of
basic rules for their reporting [3]. In analogy with the
REMARK guidelines, we propose a checklist of 20 items,
grouped according to the generally used headings in a research
paper: Introduction, Material and methods, Results, and
Discussion. We have put these together in a table and will dis-
cuss each of them briefly. The intention of our commentary is to
increase awareness of the need for more standardization and to
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stimulate discussion, in order to get to a generally accepted
approach to standardized reporting of histopathological studies
(Table 1).
The checklist
1. State the marker of interest, study objectives, and work-
ing hypotheses.
In order to understand the rationale (why this particular
marker) and potential clinical applications (what is needed
for this particular condition), a description of the marker
of interest, study objectives, and a working hypotheses are
necessary. Describe what is known on the biology of the
marker, methods to detect and quantify the marker, and
why the marker might be of clinical interest. A working
hypothesis should be formulated as a rule in terms that can
be tested statistically.
2. Describe patient characteristics and inclusion and exclu-
sion criteria.
Describe the clinical context of the study. Describe
why a particular cohort of patients was selected and the
criteria used to define the cohort, which includes inclu-
sion and exclusion criteria. Describe clinical details of
the cohort in relation to potential use of the marker of
interest. As an example, when the working hypothesis is
that a marker might have a different prognostic value in
different stages of disease, disease stage is an essential
element in the description of patient data.
3. Describe treatment details.
Treatment (neoadjuvant, adjuvant, first line, second
line, etc.) is intended to alter the disease course of a
patient. Different treatment modalities might not be dis-
tributed equally between groups with or without the bio-
marker, and this will become an important confounding
factor when correlation between outcome and marker
expression is looked for. Moreover, treatment might also
have an influence on marker expression if the patient
was treated prior to the moment the sample was taken,
which will be a confounding factor in the analysis of the
impact of the biomarker. When treatment information is
missing, this should be specifically stated, and in studies
on marker expression in relation to treatment response,
such patients should be excluded.
4. Describe the type of material used.
Tissue samples used in retrospective studies are often
convenience collections, which potentially run a serious
risk of collection bias [4]. Authors should report why
and how the specimens were collected and how the spec-
imen was handled (primary tumor site or metastatic le-
sion, biopsy or resection, formalin-fixed paraffin-em-
bedded or frozen tumor tissue). Where possible, data
on preanalytical handling of specimens should also be
given, in order to clarify potential confounding effects
associated with sample condition [5].When control sam-
ples are used, their origin should be stated as well as how
they were selected. Control samples should fit into the
experimental design based upon the working hypothesis,
to avoid problems of unexpected differences between
control and patient samples. Authors should report
methodological variables as much as possible according
to MISFISHIE guidelines [1]).
5. Specify how expression of the biomarker was assessed.
A detailed description of the criteria for assessment of
the presence or absence of the biomarker at tissue level
Table 1 Proposed items for reporting histopathology studies
Introduction
1. State the marker of interest, the study objectives, and hypotheses
Material and methods
2. Describe patient characteristics, and inclusion and exclusion criteria
3. Describe treatment details
4. Describe the type of material used
5. Specify how expression of the biomarker was assessed
6. Describe the number of independent (blinded) scorers and how they
scored
7. State the method of case selection, study design, origin of the cases,
and time frame
8. Describe the end of the follow-up period and median follow-up time
9. Define all clinical endpoints examined
10. Specify all applied statistical methods
11. Describe how interactions with other clinical/pathological factors
were analyzed
Results
12. Describe the number of patients included in the analysis and reason
for dropout
13. Report patient/disease characteristics (including the biomarker of
interest) with the number of missing values
14. Describe the interaction of the biomarker of interest with
established prognostic variables
15. Include at least 90 % of initial cases included in univariate and
multivariate analyses
16. Report the estimated effect (relative risk/odds ratio, confidence
interval, and p value) in univariate analysis
17. Report the estimated effect (hazard rate/odds ratio, confidence
interval, and p value) in multivariate analysis
18. Report the estimated effects (hazard ratio/odds ratio, confidence
interval, and p value) of other prognostic factors included in
multivariate analysis
Discussion
19. Interpret the results in context of the working hypothesis elaborated
in the introduction and other relevant studies; include a discussion of
limitations of the study.
20. Discuss potential clinical applications and implications for future
research
FOI factor of interest, RR relative risk, OR odds ratio, CI confidence
interval, HR hazard ratio, UV univariate, MV multivariate
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allows evaluation of potential shortcomings but also will
enable future researchers to reproduce the study. Some
retrospective studies on classical pathological markers
tend to extract data from pathology reports, instead of
rereading the slides or repeating marker expression
analysis for the purpose of the investigation. This runs
a risk of heterogeneity between method runs or methods
applied and problems of lack of inter-individual repro-
ducibility in reading the results. This can lead to over- or
underestimation of the number of patients expressing a
certain marker and might introduce selection bias [6].
For purely morphological (gross or microscopical)
markers, details of specimen examination, number of
slides investigated, and criteria when a marker was
called positive or negative should be provided.
6. Describe the number of independent (blinded) scorers
and how they scored
Visual assessment of a biomarker is an important
source of variance [5]. Interpretation varies between pa-
thologists, and biomarker data will be more robust if
expression of a biomarker is scored by multiple indepen-
dent observers unaware of (blinded to) the clinical pa-
rameter of interest (such as outcome). Justification of the
chosen method of and criteria for (semi-)quantitative
assessment should be provided in detail.
7. State the method of case selection, study design, origin
of the cases, and time frame.
Important determinants of the reliability of study re-
sults are study design and method of patient selection.
Selection of cases according to clinical or pathological
parameters (for example patients selected according to
age, only T4 or N0 tumors) may introduce bias; there-
fore, details of case selection should be reported. Stating
where the patients came from might provide relevant
information regarding the patient population (for exam-
ple a patient population from a tertiary referral hospital
might differ significantly from that of a primary care
center). The time frame (when cases were recruited or
diagnosis was made) should also be mentioned because
therapies change over time which might affect outcome.
8. State the end of the follow-up period and median follow-
up time.
In many studies, outcome is the time to an event (e.g.,
recurrence, death), and follow-up should be long enough
to make sure that events can happen. If, for example, a
biomarker is associated with the risk of dissemination,
follow-up should be long enough to allow this effect to
be observed. Follow-up usually ends at a specific point
in time (notably this date and the median follow-up time
should be stated).
9. Define all clinical endpoints examined.
In histopathology studies, common endpoints include
death and discovery of recurrence. Endpoints used in
survival analysis are not always clearly defined.
Analysis of time to death might include deaths from
any cause or cancer-specific deaths. A clear distinction
should be made between overall survival, disease-
specific survival, and recurrence-free survival.
Definition of parameters defining recurrence of disease
should be clear. Recurrence might include local recur-
rence or distant metastasis or both. Local recurrence and
distant metastases are two biologically different events,
and the effect of a biomarker on each of these might be
different. Lack of clearly defined endpoints may lead to
misinterpretation of its association with a biomarker and
preclude inclusion of a publication in a meta-analysis.
10. Specify all applied statistical methods.
If the statistical methods used in a biomarker study
are not clearly specified, it will be difficult or impossible
for the reader to interpret the results or reproduce and
validate the findings. Rather often the amount of detail
provided in publications is marginal. Mathoulin-
Pelissier et al. concluded that 68 % of the articles pub-
lished in major journals reported insufficient information
regarding the survival analysis [7].
11. Describe how interactions with other clinical/
pathological variables were analyzed.
Any seemingly interesting biomarker might interact
with established clinical or pathological factors.
Methods used to assess potential interactions with other
variables should be described. The interactions are
essential to evaluate whether or not found associations
have independent value. All included variables should
be clearly defined, and the choice of variables included
in the study has to be justified (why variables included
in the study were retained while others were left out).
12. Describe the number of patients included in the analysis
and reasons for dropout.
In retrospective biomarker studies, the number of
cases included in analysis is often lower than the initial
number of cases included in the study. This is mainly due
to missing values, such as impossibility to (re-)evaluate
staining results or missing outcome data. A solution
often chosen is to restrict the analyses to samples with
complete data. However, this may introduce selection
bias when samples with missing data are not typical for
the whole study population. It is therefore necessary to
state the number of patients and events included in each
analysis. Only with this information is it possible to
assess the reliability of reported findings.
13. Report patient/disease characteristics (including the bio-
marker of interest) with number of missing values.
A detailed description of patient characteristics and
relevant histopathological parameters is needed to assess
whether or not the patient cohort included in the study is
representative for the condition under scrutiny. Obvious
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patient characteristics are age and gender, but parameters
such as ethnicity, performance status, or medical history
might be relevant. In case of cancer, characteristics of the
lesion should include parameters defining TNM stage.
14. Describe the interaction of the factor of interest with
established prognostic variables.
As stated in point 11, a new biomarker is only useful
if its effect is maintained when interaction with other
prognostic factors is ruled out, or if its assessment is
(quantitatively or qualitatively) superior in comparison
with established prognostic variables. For evaluation of
clinical value, the potential interactions between a new
biomarker and established prognostic variables should
therefore be reported.
15. Include at least 90 % of initial cases in univariate and
multivariate analyses.
As mentioned above, due to missing values, the num-
ber of cases included in statistical analysis is often lower
than the initial number of cases included in the study.
The risk of attrition bias will increase along with the
proportion of cases not included in statistical analysis
[6]. To minimize attrition bias, Smith et al. proposed that
at least 90 % of the selected cohort should be included in
the statistical analysis [8]. Sub-analyses should be
avoided because of the high risk of false-positive find-
ings due to increasingly small patient numbers.
16. Report the estimated effect (relative risk/odds ratio, con-
fidence interval, and p value provided) of the biomarker
in univariate analysis.
Establishing a biomarker’s potential association with
clinical outcome is the key subject in biomarker re-
search. In univariate analysis, the relationship between
the biomarker and outcome can be assessed without ad-
justment for additional variables. Relative risks or odds
ratios with their associated confidence intervals and p-
values should be given, regardless of statistical signifi-
cance. Kaplan-Meier curves should be included when
illustrative, but p values from log rank tests should be
given regardless of statistical significance. Univariate
analysis should also be performed for all other variables
and presented in a summarizing table.
17. Report the estimated effect (hazard ratio, confidence in-
terval, and p value provided) of the biomarker in multi-
variate analysis.
In multivariate analysis, the association between a
biomarker and clinical outcome can be established,
correcting for established prognostic variables. Authors
should report which prognostic variables were included
in multivariate analysis. As a rule, significant factors
identified in univariate analysis should all be included.
Hazard ratios with associated confidence intervals and
p values should be given, regardless of statistical
significance.
18. Report estimated effects (hazard ratio, confidence inter-
val, and p values provided) of other prognostic factors
included in multivariate analysis.
Within a study, significant findings are more likely to
be reported than non-significant findings. In order to
prevent selective reporting bias, authors should report
the effects of all prognostic factors included in the mul-
tivariable analysis; not only the marker of interest or the
significant findings.
19. Interpret the results in the context of the working hypoth-
esis elaborated in the introduction and other relevant
studies; include a discussion of limitations of the study.
Authors should critically evaluate their findings,
mentioning limitations of the study and possible biases.
A good discussion will allow the reader to retain a bal-
anced perception of the importance of the results of the
study.
20. Discuss potential clinical applications and implications
for future research.
The intention of biomarker studies is to develop new
disease-associated parameters of which the contribution
to clinical decision-making reaches beyond that of
existing parameters included in the standard of care. A
statistically significant association between a marker and
disease outcome might seem promising, but authors
should mention in the discussion which steps will be
taken in order to eventually reach implementation of
the marker in patient care.
Conclusion
Adherence to guidelines on reporting, whenever possible,
should facilitate a clear perception by the reader of the inher-
ent qualities of the reported study, and we presume that it
might also have a positive effect on study quality, for as much
as the checkpoints we propose are already used when the
study is planned. The 20 checkpoints we propose speak for
themselves. We paid no attention to sample size calculations,
because most histopathological studies are retrospective and
based upon convenience case collections that were not set up
to answer specific questions well defined before the collection
was started. Checking model assumptions, standardized mod-
el making and model validation is unusual in histopathology
research but might become more mainstream when this is
more often performed in the context of clinical trials. For a
biomarker identified in a retrospective study, we consider ex-
ternal validation by independent groups on separate patient
cohorts of much greater value than internal validation. Our
checkpoints might be of help for investigators who study
tissue-based biomarkers, reviewers of manuscripts, and re-
searchers performing meta-analyses. They should ultimately
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support quality improvement of histopathological studies and
implementation of new findings into daily practice. We wel-
come feedback from the scientific community to improve on
and facilitate implementation of our list of checkpoints.
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